REGENXBIO to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Rhea-AI Summary

REGENXBIO Inc. (Nasdaq: RGNX) has announced its participation in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference on Thursday, August 15, 2024. The company will be part of a panel discussion titled 'The Evolving Therapeutic Landscape of AMD' scheduled for 9:00 a.m. EDT.

Interested parties can access a live webcast of the panel through the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay will be available for approximately 30 days following the presentation, providing an opportunity for those unable to attend the live event to catch up on the discussion.

News Market Reaction

-1.25%

1 alert

-1.25% News Effect

On the day this news was published, RGNX declined 1.25%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

ROCKVILLE, Md., Aug. 8, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the H.C. Wainwright 4^th Annual Ophthalmology Virtual Conference on Thursday, August 15, 2024.

H.C. Wainwright 4^th Annual Ophthalmology Virtual Conference
Panel: The Evolving Therapeutic Landscape of AMD
Date/Time: Thursday, August 15, 2024 at 9:00 a.m. EDT
Location: Virtual

A live webcast of the panel can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.

ABOUT REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, RGX-202 for the treatment of Duchenne and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO's AAV Therapeutic platform, including Novartis' ZOLGENSMA® for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people. For more information, please visit www.regenxbio.com.

Contacts:

Dana Cormack
Corporate Communications
dcormack@regenxbio.com 

Investors:
Chris Brinzey, ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-participate-in-the-hc-wainwright-4th-annual-ophthalmology-virtual-conference-302217608.html

SOURCE REGENXBIO Inc.

FAQ

When is REGENXBIO (RGNX) participating in the H.C. Wainwright Ophthalmology Conference?

REGENXBIO (RGNX) is participating in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference on Thursday, August 15, 2024.

What panel is REGENXBIO (RGNX) participating in at the 2024 H.C. Wainwright conference?

REGENXBIO (RGNX) is participating in the panel titled 'The Evolving Therapeutic Landscape of AMD' at the 2024 H.C. Wainwright Ophthalmology Conference.

What time is REGENXBIO's (RGNX) panel at the H.C. Wainwright conference on August 15, 2024?

REGENXBIO's (RGNX) panel at the H.C. Wainwright conference is scheduled for 9:00 a.m. EDT on August 15, 2024.

How can I watch REGENXBIO's (RGNX) panel at the 2024 H.C. Wainwright Ophthalmology Conference?

You can watch a live webcast of REGENXBIO's (RGNX) panel through the Investors section of the company's website at www.regenxbio.com.

How long will the replay of REGENXBIO's (RGNX) panel be available after the August 15, 2024 conference?

An archived replay of REGENXBIO's (RGNX) panel will be available for approximately 30 days following the presentation on August 15, 2024.